Containing Emulsions, Dispersions, Or Solutions Patents (Class 424/455)
  • Patent number: 10328022
    Abstract: The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule comprising one or more antiprogestins.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: June 25, 2019
    Assignee: REPROS THERAPEUTICS INC.
    Inventors: Joseph S. Podolski, Kuang Hsu
  • Patent number: 10314793
    Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 11, 2019
    Assignee: Soft Gel Technologies, Inc.
    Inventor: Michael Fantuzzi
  • Patent number: 10166192
    Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: January 1, 2019
    Inventor: Michael Fantuzzi
  • Patent number: 10154967
    Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 18, 2018
    Assignee: XI'AN LIBANG PHARMACEUTICAL CO., LTD
    Inventors: Rutao Wang, Tao Chen, Shupan Guo, Huijing Hu, Long An, Weijiao Wang
  • Patent number: 10028925
    Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: July 24, 2018
    Assignee: Patheon Softgels, Inc.
    Inventors: Nachiappan Chidambaram, Aqeel A Fatmi
  • Patent number: 10022344
    Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 17, 2018
    Assignee: Patheon Softgels, Inc.
    Inventors: Nachiappan Chidambaram, Aqeel A. Fatmi
  • Patent number: 10017782
    Abstract: RNA prepared by in vitro transcription using a polymerase chain reaction (PCR)-generated template can be introduced into a cell to modulate cell activity. This method is useful in de-differentiating somatic cells to pluripotent, multipotent, or unipotent cells; re-differentiating stem cells into differentiated cells; or reprogramming of somatic cells to modulate cell activities such as metabolism. Cells can also be transfected with inhibitory RNAs, such as small interfering RNA (siRNA) or micro RNA (miRNA), or combinations thereof to induce reprogramming of somatic cells. For example, target cells are isolated from a donor, contacted with one or more RNA's causing the cells to be de-differentiated, re-differentiated, or reprogrammed in vitro, and administered to a patient in need thereof. The resulting cells are useful for treating one or more symptoms of a variety of diseases and disorders, for organ regeneration, and for restoration of the immune system.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: July 10, 2018
    Assignee: Yale University
    Inventors: Peter M. Rabinovich, Sherman M. Weissman, Erkut Bahceci, Marina E. Komarovskaya
  • Patent number: 10004693
    Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: June 26, 2018
    Assignee: Flamel Ireland Limited
    Inventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
  • Patent number: 9895367
    Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: February 20, 2018
    Assignee: NATCO PHARMA LIMITED
    Inventors: Durga Maheswari Parvataneni, Siddhartha Yedluri, Venkata Satyanarayana Appadwedula, Kali Satya Bhujanga Rao, Venkaiah Chowdary Nannapaneni
  • Patent number: 9848617
    Abstract: Provided is a coagulant composition for tofu having a sufficient slow-acting property in coagulation of soymilk in a tofu production process as a necessary condition, and being capable of developing the original flavor of tofu originated in a raw material soybean and its pressed soymilk as a sufficient condition, the coagulant composition being obtained by dispersing an inorganic salt-based coagulant for tofu in a mixture of a natural wax and an edible oil or fat.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: December 26, 2017
    Assignee: TAIKI PRODUCT, INC.
    Inventors: Kenzou Kanai, Yukitaka Tanaka
  • Patent number: 9802984
    Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, an isolated peptide comprising the amino acid sequence LRRFSTAPFAFIDINDVINF, which exhibits anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models is disclosed. The isolate peptide also exhibits anti-lymphangiogenic and directly anti-tumorigenic properties.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: October 31, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Aleksander S. Popel, Niranjan B. Pandey, Esak Lee, Jordan J. Green, Ron B. Shmueli
  • Patent number: 9693978
    Abstract: Liquid and semi-solid pharmaceutical compositions, which can be administered in liquid form or can be used for preparing capsules, are described herein. The composition comprises the salt of one ore more active agents, polyethylene glycol, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of active agent, and water. The pH of the composition is adjusted within the range of 2.5-7.5. The de-ionizing agent causes partial de-ionization (neutralization) of the salt of the active agent resulting in enhanced bioavailability of salts of weakly acidic, basic or amphoteric active agents as well as lesser amounts of polyethylene glycol (PEG) esters.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventors: Nachiappan Chidambaram, Aqeel Fatmi
  • Patent number: 9693979
    Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventors: Nachiappan Chidambaram, Aqeel A Fatmi
  • Patent number: 9687496
    Abstract: It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: June 27, 2017
    Assignee: ASARINA PHARMA AB
    Inventors: Torbjörn Bäckström, Anders Carlsson
  • Patent number: 9592296
    Abstract: The invention relates to a pharmaceutical composition for oral administration comprising or consisting of (i) 10 to 30% weight, of at least one pharmaceutically active substance selected from the group consisting of water-soluble, oxidatively-degradable statins, preferably atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or a combination thereof, (ii) 0.01 to 3% weight, of a first anti-oxidatively active substance (A1), (iii) 0.01 to 3% weight, of a second anti-oxidatively active substance (A2) that differs from the first anti-oxidatively active substance (A1), and (iv) 60 to 85% weight of at least one additive, selected from the group consisting of filler, binder, flow-regulating agent, disintegrant and anti-blocking agent or a combination thereof, and the use of the pharmaceutical composition in medicine.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: March 14, 2017
    Assignee: HEXAL AG
    Inventors: Theresa Taeubrich, Patrick Rother
  • Patent number: 9572894
    Abstract: The present invention provides three-component compositions comprising microparticles, a tumor antigen, a first immune adjuvant, and a second immune adjuvant. Also provided are chemo-immunotherapeutic compositions comprising microparticles, a chemotherapeutic agent, and an immune adjuvant.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: February 21, 2017
    Assignee: The University of Iowa Research Foundation
    Inventors: Aliasger K. Salem, Sean M. Geary, George J. Weiner, Caitlin Lemke, Yogita Krishnamachari
  • Patent number: 9555003
    Abstract: Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not come to contact with each other directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: January 31, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Maojian Gu, Qilan Zheng, Chao Xu, Ning Li, Guixian Chen, Lan Zheng, Min Wang, Lintao Jiang
  • Patent number: 9468602
    Abstract: The present invention refers to a microemulsion formulation suitable for preventing assembly of amphiphilic drug molecules which may cause hypersensitivity reactions and other unwanted side effects.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: October 18, 2016
    Assignee: AZAD Pharma AG
    Inventors: Fabio Carli, Elisabetta Chiellini, Van Van Khov-Tran, Mihran Baronian
  • Patent number: 9314441
    Abstract: A bi-phasic pharmaceutical composition for oral administration including one or more solid active ingredient containing particles dispersed within a semi-solid carrier formulation. The solid particles include a coating with pH-triggered drug release properties and the semi-solid carrier formulation is formulated at a pH that is different than the pH at which the active ingredient release properties of the coating are triggered. Also described is a delivery system for delivery of the bi-phasic pharmaceutical composition including the bi-phasic pharmaceutical composition described above and a dispenser pouch formed from flexible laminate sheets. Further, a process for manufacturing the two-phase pharmaceutical delivery system is described including the filling the bi-phasic pharmaceutical composition into flexible dispenser pouches, which allows the patient to squeeze and dispense the contents of the package directly into the oral cavity.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: April 19, 2016
    Assignee: R.P. Scherer Technologies, LLC
    Inventor: Hans Jürgen Maier
  • Patent number: 9314435
    Abstract: The invention discloses stable formulations of acetylsalicylic acid or salts thereof, omega-3 fatty acids and amylose in soft gelatin capsules.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: April 19, 2016
    Assignee: ALTERGON S.A.
    Inventors: Simone Carucci, Alberto Bernareggi, Maurizio Marchiorri, Marco Pontiggia
  • Patent number: 9278077
    Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: March 8, 2016
    Assignee: TAMARISK TECHNOLOGIES GROUP, LLC
    Inventor: Daniel R. DeBrouse
  • Patent number: 9205044
    Abstract: An aqueous pharmaceutical preparation for administration of a slightly soluble PDE4 inhibitor is described.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: December 8, 2015
    Assignee: TAKEDA GMBH
    Inventor: Rudolf Linder
  • Patent number: 9192896
    Abstract: A method for producing a product comprising at least one selected from C2+ hydrocarbons, oxygenates, and combinations thereof from light gas comprising one or more of carbon dioxide, methane, ethane, propane, butane, pentane, and methanol by forming a dispersion of light gas in a liquid feed, wherein the dispersion is formed at least in part with high shear forces and wherein at least one of the liquid feed and the light gas is a hydrogen source. A system for carrying out the method is also presented.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: November 24, 2015
    Assignee: H R D Corporation
    Inventors: Abbas Hassan, Ebrahim Bagherzadeh, Rayford G. Anthony, Gregory Borsinger, Aziz Hassan
  • Patent number: 9060927
    Abstract: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a clear liquid, neutral pH, in a multi-use sterile vial. In an alternative embodiment, the insulin is provided as a powder in a sterile vial.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: June 23, 2015
    Assignee: Biodel Inc.
    Inventors: Solomon S. Steiner, Roderike Pohl, Ming Li, Robert Hauser
  • Patent number: 9056088
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: June 16, 2015
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 9034375
    Abstract: A water-in-oil emulsion composition which contains a low water-solubility but oil-soluble ultraviolet absorber, and which exhibits excellent ultraviolet light protection and stability. The composition contains (a) an aqueous dispersion of an oil-soluble ultraviolet absorber; (b) a polyoxyalkylene-modified polysiloxane having a molecular mass of at least 2000; and (c) at most 5 mass % of an ultraviolet scattering agent; and component (a) being contained in the internal phase. Component (a) is preferably an aqueous dispersion of a complex particle of an oil-soluble ultraviolet absorber and an organic polymer.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: May 19, 2015
    Assignee: SHISEIDO COMPANY, LTD.
    Inventors: Yuko Nagare, Kazuhiro Yamaguchi
  • Patent number: 9023387
    Abstract: The present invention is directed to a transfer resistant and long wear composition containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) at least one volatile solvent; (e) at least one non-volatile solvent capable of solubilizing the oil-soluble polar modified polymer; (e) at least one surfactant; and (f) at least one colorant.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: May 5, 2015
    Assignee: L'Oreal
    Inventors: Hy Si Bui, Mohamed Kanji, Susan Halpern, Christine Chen
  • Patent number: 9023386
    Abstract: The present invention provides microspheres comprising a plurality of nanocapsules accommodated in a gel forming polymer, the plurality of nanocapsules comprising an oil core carrying a non hydrophilic active agent and a shell of polymeric coating. The invention also provides a method for preparing the microspheres of the invention, pharmaceutical compositions comprising the same as well as methods of use of the microspheres, specifically, in therapeutic, cosmetic and diagnostic applications.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: May 5, 2015
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Shimon Benita, Alona Rom, Taher Nasser
  • Patent number: 9017720
    Abstract: The present invention is directed to seamless capsules and methods for making seamless capsules having a high oil content as described herein. More specifically, the present invention is directed to seamless capsules, and methods for making seamless capsules, made from a process involving the steps of: (a) preparing an emulsion comprising oil, water, an emulsifier, and at least one of a water-soluble monovalent metal salt, polyvalent metal salt, and an acid, wherein said oil is present in an amount of at least 50% by weight of said emulsion; with the proviso that said emulsion does not contain marmelo mucilage; and (b) adding portions of said emulsion to an aqueous gelling bath comprised of at least one ionic polysaccharide thereby encapsulating said portions of said emulsion in a polysaccharide gel membrane, and optionally (c) drying the resulting capsules by removing water.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: April 28, 2015
    Assignee: FMC Bioploymer AS
    Inventors: Peder Oscar Andersen, Olav Gåseröd, Christian Klein Larsen
  • Patent number: 9000048
    Abstract: The present invention provides therapeutic formulations, including therapeutic emulsions and nanoemulsions, and related methods for the delivery of fluorinated therapeutic compounds, including an important class of low boiling point perfluorinated and/or perhalogenated volatile anesthetics. Emulsion-based fluorinated volatile anesthetic formulations compatible with intravenous administration are provided that are capable of delivering and releasing amounts of fluorinated volatile anesthetic compounds effective for inducing and maintaining anesthesia in patients. Intravenous delivery of the present emulsion-based fluorinated volatile anesthetic formulations permits anesthetic levels in a patient to be selectively adjusted very rapidly and accurately without the need to hyperventilate patients and without the use of irritating agents.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: April 7, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Sandro Mecozzi, Robert A. Pearce, Jonathan P. Fast
  • Publication number: 20150079164
    Abstract: The present disclosure relates to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with acne and/or eczema (dermatitis).
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Applicant: Pronova Biopharma Norge AS
    Inventors: David A. Fraser, Alexis Garras
  • Patent number: 8974820
    Abstract: The invention provides an apparatus for producing soft gel capsules having encapsulated therein microparticles, nanoparticles and fluids, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies; (d) a liquid fill system (medicine pump system); (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) one or more microgranule or nanogranule feeders located on each side of the rotary dies, said feeders being synchronized to rotate at the same tangential speed as the rotary dies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: March 10, 2015
    Assignee: Procaps SAS
    Inventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Willmer Herrera
  • Patent number: 8968775
    Abstract: Provided are pharmaceutical carriers based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented by formulated for topical administration to the eye.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 3, 2015
    Assignee: EyeCRO, LLC
    Inventors: Ronald A. Wassel, Fadee G. Mondalek, Rafal A. Farjo, Alexander B. Quiambao, Didier J. Nuño
  • Publication number: 20150017238
    Abstract: Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 15, 2015
    Applicant: Oramed, Ltd.
    Inventor: Miriam Kidron
  • Patent number: 8916204
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 23, 2014
    Assignee: Abraxis BioSciences, LLC
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 8911777
    Abstract: An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized tacrolimus throughout the entire gastrointestinal tract. The composition may be used, for example, for treatment or prevention of solid organ transplant rejection.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: December 16, 2014
    Assignee: Sigmoid Pharma Limited
    Inventor: Ivan Coulter
  • Patent number: 8900629
    Abstract: The present disclosure provides rapidly dissolving oral capsules and films comprising pullulan, a plasticizer, and a dissolution enhancing agent.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 2, 2014
    Assignee: University of Kansas
    Inventors: Roger A. Rajewski, Lian G. Rajewski, John L. Haslam
  • Patent number: 8889161
    Abstract: The present invention is directed to compositions, products and methods useful for bone and tooth mineralization. The compositions comprise polymer microcapsules containing aqueous salt solutions. The shells of the microcapsules can be semi-permeable or impermeable. Solutions of calcium, fluoride and phosphate salts are particularly useful in the compositions of the invention. The microcapsules are preferably prepared by surfactant free inverse emulsion interfacial polymerization. Bone products include cements, scaffolds and bioactive glass. Dental products include pastes, gels, rinses and many other dental materials.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: November 18, 2014
    Assignee: Premier Dental Products Company
    Inventors: Mark A. Latta, Stephen M. Gross, William A. Mchale
  • Publication number: 20140335172
    Abstract: Disclosed herein is a novel rinsing agent, which may be suitable for use in surgical, and, in particular, ophthalmological procedures. The rinsing agent may by employed to remove emulsified oil droplets from the eye cavity. Also disclosed is a method for effectively removing emulsified silicone oil droplets remaining in the eye cavity after ophthalmological procedures using the disclosed rinsing agent in order to prevent the development of long-term complications associated with the emulsified oil droplets.
    Type: Application
    Filed: April 29, 2014
    Publication date: November 13, 2014
    Applicant: THE UNIVERSITY OF HONG KONG
    Inventors: Ho Cheung SHUM, Sai Hung WONG, Yau Kei CHAN
  • Publication number: 20140314840
    Abstract: The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 23, 2014
    Inventor: Michael Fantuzzi
  • Patent number: 8865021
    Abstract: The present invention relates to compositions containing at least one cationic peptide active agent, at least one neutral structure forming amphiphile, at least one anionic structure forming amphiphile and optionally at least one solvent wherein the composition is in the form of a non-lamellar phase structure and/or forms a nonlamellar phase structure on exposure to body fluids. The invention also relates to methods for protecting peptides from enzymic degredation in vivo and to compositions in which the peptide active agent is so protected.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: October 21, 2014
    Assignee: Camurus AB
    Inventors: Fredrik Joabsson, Fredrik Tiberg
  • Patent number: 8865032
    Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 21, 2014
    Assignee: Soft Gel Technologies, Inc.
    Inventor: Michael Fantuzzi
  • Patent number: 8865209
    Abstract: A method is disclosed for self-administered delivery of a pre-determined amount of liquid medication where a portion of the liquid medication is administered sublingually and the remaining portion is swallowed for and gastro-intestinal absorption.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 21, 2014
    Inventor: Yuri Busiashvili
  • Publication number: 20140302134
    Abstract: The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 9, 2014
    Inventor: Roland Saur-Brosch
  • Patent number: 8840934
    Abstract: A method to treat a condition in a patient comprising administering to the patient a therapeutically effective amount of a NH4Cl dosage form, a method for stimulating endogenous interferon production, and related methods, systems and dosage form housings.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: September 23, 2014
    Assignee: Rainbow Pharmaceutical SA
    Inventor: Diamantis Kiassos
  • Patent number: 8840923
    Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 23, 2014
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
  • Publication number: 20140271791
    Abstract: A composition for human consumption includes a base composition having a pH of about 2 to about 5 and encapsulated caffeine dispersed throughout at least a portion of the base composition. The encapsulated caffeine can be a caffeine complex. The base composition can include a liquid or a food. An oral pouch product includes a porous pouch wrapper, an inner botanical filling material contained within the pouch wrapper, and encapsulated caffeine dispersed throughout at least a portion of the oral pouch product. The encapsulated caffeine is included in the composition and/or the oral pouch product an amount sufficient to release about 50 mg to about 200 mg of caffeine. The composition can provide immediate release of caffeine and/or release of caffeine over an extended period of time.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: ALTRIA CLIENT SERVICES INC.
    Inventors: Munmaya K. Mishra, Gerd Kobal
  • Patent number: 8835509
    Abstract: The present invention discloses a pharmaceutical composition in the form of self nano emulsifying drug delivery formulation comprising curcuminoids. The pharmaceutical composition of the present invention shows an enhanced drug loading ability, better stability and an improved bioavailability. The composition of the present invention comprises of a pharmaceutically effective amount of a curcuminoid, an oil phase, a surfactant and a co surfactant.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: September 16, 2014
    Assignees: Arbro Pharmaceuticals Ltd., Jamia Hamdard (Hamdard University)
    Inventors: Kanchan Kohli, Sunny Chopra, Saurabh Arora, Roop K. Khar, Kolappa K. Pillai
  • Publication number: 20140255481
    Abstract: The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicant: NOVO NORDISK A/S
    Inventor: Florian A. Foeger
  • Patent number: 8815284
    Abstract: The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: August 26, 2014
    Assignee: pSivida US, Inc.
    Inventors: Hong Guo, Jianbing Chen, Dongling Su, Paul Ashton